尽管乳腺癌在精准医疗方面取得了先导作用，但仍需要更多研究来提高早期患者的治愈率，并在转移状态下以最佳生活质量延长生存期。去年，由于免疫疗法对三阴性乳腺癌患者生存率的显著影响以及抗体药物联合的令人兴奋的结果，这些目标取得了重大进展。简明语言摘要：开发新药和生物标记物来选择受益患者对于提高乳腺癌患者的生存率至关重要。去年，抗体药物联合治疗的出现和免疫疗法的潜力得到重申是最重要的发现。© 2023 The Authors. Cancer published by Wiley Periodicals LLC on behalf of American Cancer Society.

Although breast cancer has led the way toward precision medicine, more research is still needed to increase curation rates in patients with early disease and to prolong survival with an optimal quality of life in the metastatic setting. Last year, big advances were achieved toward these goals thanks to the significant impact of immunotherapy on survival in triple-negative breast cancer and the exciting results of antibody-drug conjugates. PLAIN LANGUAGE SUMMARY: The development of new drugs and biomarkers to select those patients who will benefit of them are crucial in improving survival in breast cancer. Last year, the emergence of antibody-drug conjugates and the reaffirmation of the potential of immunotherapy in breast cancer were the most important findings.© 2023 The Authors. Cancer published by Wiley Periodicals LLC on behalf of American Cancer Society.